FDA Approval Alert: The Need-to-Know | Nivolumab/Ipilimumab in Unresectable/Metastatic Hepatocellular Carcinoma

In April 2025, the FDA approved nivolumab plus ipilimumab for patients with unresectable or metastatic hepatocellular carcinoma.

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC
FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC
Article
Apr 11, 2025 2:38 PM
Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.